Intech Biopharm (ROCO:6461) Cyclically Adjusted Revenue per Share: NT$0.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
54 GF Score
Price NT$16.50
GF Value NT$82.82
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm Cyclically Adjusted Revenue per Share?

Intech Biopharm ROCO:6461 +5.77% 54 Cyclically Adjusted Revenue per Share is NT$0.33 as of Mar. 2026. GuruFocus rates ROCO:6461 with a GF Score™ of 54/100 and a GF Value™ of NT$82.82 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Intech Biopharm's adjusted revenue per share for the three months ended in Mar. 2026 was NT$0.099. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$0.33 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Intech Biopharm's average Cyclically Adjusted Revenue Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-08), Intech Biopharm's current stock price is NT$16.50. Intech Biopharm's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$0.33. Intech Biopharm's Cyclically Adjusted PS Ratio of today is 50.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Intech Biopharm was 105.82. The lowest was 44.09. And the median was 59.93.


Intech Biopharm  (ROCO:6461) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Intech Biopharm's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=16.50/0.33
=50.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Intech Biopharm was 105.82. The lowest was 44.09. And the median was 59.93.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Intech Biopharm Cyclically Adjusted Revenue per Share Related Terms


Intech Biopharm Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Intech Biopharm's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intech Biopharm Cyclically Adjusted Revenue per Share Chart

Intech Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.27 0.33

Intech Biopharm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.33 0.33 0.33 0.33

ROCO:6461 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Intech Biopharm's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intech Biopharm Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's Cyclically Adjusted PS Ratio falls into.


ROCO:6461
54GF Score
Intech Biopharm Ltd ROCO:6461
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intech Biopharm Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intech Biopharm's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.099/330.2130*330.2130
=0.099

Current CPI (Mar. 2026) = 330.2130.

Intech Biopharm Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.025 241.428 0.034
201612 0.070 241.432 0.096
201703 0.058 243.801 0.079
201706 0.049 244.955 0.066
201709 0.052 246.819 0.070
201712 0.063 246.524 0.084
201803 0.056 249.554 0.074
201806 0.047 251.989 0.062
201809 0.047 252.439 0.061
201812 0.062 251.233 0.081
201903 0.051 254.202 0.066
201906 0.048 256.143 0.062
201909 0.053 256.759 0.068
201912 0.043 256.974 0.055
202003 0.050 258.115 0.064
202006 0.062 257.797 0.079
202009 0.034 260.280 0.043
202012 0.055 260.474 0.070
202103 0.068 264.877 0.085
202106 0.040 271.696 0.049
202109 0.133 274.310 0.160
202112 0.123 278.802 0.146
202203 0.092 287.504 0.106
202206 0.047 296.311 0.052
202209 0.022 296.808 0.024
202212 0.036 296.797 0.040
202303 0.030 301.836 0.033
202306 0.083 305.109 0.090
202309 0.057 307.789 0.061
202312 0.041 306.746 0.044
202403 0.106 312.332 0.112
202406 0.038 314.175 0.040
202409 0.063 315.301 0.066
202412 0.076 315.605 0.080
202503 0.055 319.799 0.057
202506 0.608 322.561 0.622
202509 0.044 324.800 0.045
202512 0.029 324.054 0.030
202603 0.099 330.213 0.099

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$0.33 mean?
Intech Biopharm (ROCO:6461) has a Cyclically Adjusted Revenue per Share of NT$0.33 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Intech Biopharm and its competitors.
Is Intech Biopharm's Cyclically Adjusted Revenue per Share too high?
Intech Biopharm's current Cyclically Adjusted Revenue per Share is NT$0.33. Overall, Intech Biopharm has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Intech Biopharm's Cyclically Adjusted Revenue per Share of NT$0.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Intech Biopharm and its competitors. Intech Biopharm's current Cyclically Adjusted Revenue per Share is NT$0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$82.82, compared to a current price of NT$16.50 — trading 80.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$0.33. Intech Biopharm's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current Cyclically Adjusted Revenue per Share is NT$0.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$16.50 is trading 80.1% below its estimated GF Value™ of NT$82.82. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • Cyclically Adjusted Revenue per Share: NT$0.33
  • GF Value™: NT$82.82 vs. price of NT$16.50 (80.1% below fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
54GF Score

Get the complete analysis for ROCO:6461

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.50
Price
NT$82.82
GF Value